Health
New Data from Aurinia Pharmaceuticals on LUPKYNIS Efficacy in Lupus Nephritis Presented at EULAR 2024
Aurinia Pharmaceuticals presented new data at the European Alliance of Associations for Rheumatology (EULAR) 2024 in Vienna, Austria, reinforcing the efficacy of LUPKYNIS in treating lupus nephritis (LN).
The AURORA Clinical Program, focusing on the safety and effectiveness of LUPKYNIS, a second-generation calcineurin inhibitor, for adult patients with active LN, was the subject of the presentation.
A propensity analysis comparing the studies in the AURORA Program to ALMS suggested that the triple immunosuppressive therapy regimen of LUPKYNIS, lower-dose MMF, and low-dose steroids resulted in significant reductions in proteinuria and steroid exposure, with comparable adverse event rates.
Results showed faster and greater reductions in proteinuria with the LUPKYNIS-based regimen, emphasizing its potential as an initial therapy for patients with active LN.
These findings support the recommendation that LUPKYNIS in combination with lower-dose MMF and steroids should be considered early in the treatment of active LN patients.
The study’s results were also recently presented at the annual European Renal Association Congress 2024, adding to the growing body of evidence supporting the efficacy of LUPKYNIS in LN treatment.
Lupus nephritis (LN), a severe manifestation of systemic lupus erythematosus (SLE), affects a significant number of individuals, particularly women and people of color, with high unmet medical needs.
Aurinia Pharmaceuticals, a biopharmaceutical company, introduced LUPKYNIS as the first oral therapy approved by the FDA and the European Commission for adult patients with active LN.
The AURORA Clinical Program, including pivotal and extension trials, highlighted the importance of LUPKYNIS in preserving kidney health and reducing reliance on high-dose glucocorticoids in LN treatment.
Aurinia’s commitment to improving health outcomes for LN patients is evident in its focus on education and transformative therapies for this population.
